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APP processing and Alzheimer 
 
Intrabody approach 
 
 
Alzheimer’s disease is the major cause of dementia in the elderly population, and its figures will increase as aging is the major risk and the population’s 
lifespan is increasing. There is a promising gene-based therapy which turns the humoral immune system outside in for intracellular immunization. 
Intracellular antibodies (intrabodies) are antibody fragments fusioned to signal sequences which allow them to stay within the cell and, if desired, direct 
them to specific compartments and organelles. In the present work we present a therapeutic alternative for combating intracellular amyloid-β production.  
The amyloid hypothesis affirms that initiation of Alzheimer’s Disease 
(AD) is elicited by excessive amyloidogenic processing of the Amyloid 
Precursor Protein (APP), producing toxic amyloid-β. Significant in vitro 
and human pathological data suggest that intraneuronal accumulation 
of Aβ peptides plays an early role in the neurodegenerative cascade.  
Intrabodies are intracellularly retained antibodies fusioned to signal 
sequences specific for intracellular compartments. Originally intrabodies 
derive from single-chain variable fragments (scFv), but recently smaller 
versions are being developed (i. e. single-domain intrabodies (sdAb)).  
Our hypothesis is that β-cleavage site-specific intrabodies can reduce 
amyloidogenic processing of APP, leading to less intracellular Aβ 
accumulation, thus preventing or slowing-down the onset of the 
disease in transgenic mice harboring mutant presenilin 1, mutant APP 
and mutant tau protein (3xTg AD mice). 
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More promising results of the ER-retained version (sdAb-KDEL) are 
expected, since the processing of APP occurs mainly in the secretory 
pathway. However, results from this sdAb format are expected to 
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Fig 1. Amyloidogenic cleavage of APP is mediated by β-secretase (BACE) followed by γ-secretase 
activity (presenilins 1/2, nicastrin, PEN2 and APH-1). An early event in AD is the intracellular 
oligomerization of Aβ, leading to toxic oligomers that can aggregate extracellularly and impair synaptic 
functionality, mitochondria homeostasis and affect the protein folding quality control of neurons. 
Fig 2.  Rationale of the intrabody 
approach. Intrabodies are generated by 
fusing the desired format of an antibody 
with a signal sequence specific for the 
desired intracellular compartment or 
organelle where the intrabody will be 
retained.  The most used versions of 
intrabodies are scFv (a light chain 
variable fragment linked to a heavy 
chain variable fragment) and sdAb (a 
single fragment retaining both affinity 
and specificity for a certain antigen). 
Fig 3. β-cleavage site-specific intrabodies will be produced by panning in vitro a sdAb phage library. Binders will be used for an in vivo panning round using an auxotrophy-based yeast-two-hybrid assay. Best binders will 
be used for assays in cell cultures and triple-transgenic AD mice. Their ability to bind APP and reduce Aβ deposition will be tested as well as their ability to reduce memory loss.  
